Literature DB >> 10914340

Mortality among three refinery/petrochemical plant cohorts. I. 1970 to 1982 active/terminated workers.

R J Lewis1, J F Gamble, G Jorgensen.   

Abstract

This study updates mortality rates for 19,075 active and terminated workers at three refinery/petrochemical plants. Mortality rates of the workers were compared with both national and state rates. The results indicated deficits of deaths for all causes, all malignant neoplasms, and respiratory and prostate cancer. The noteworthy finding was a statistically significant increase in leukemia among Louisiana male subjects (standardized mortality ratio [SMR], 181; 95% confidence interval [CI], 122 to 259), which showed suggestive trends of increasing SMRs with increasing tenure. This excess was largely due to increased chronic lymphocytic leukemia (SMR, 351; 95% CI, 168 to 645). The rate of kidney cancer remained elevated among Louisiana male subjects, but this finding was no longer significant, and there were no patterns in SMRs by tenure and latency. Mesothelioma was increased at the Louisiana (SMR, 198; 95% CI, 72 to 430) and Texas (SMR, 246; 95% CI, 99 to 507) locations. The leukemia findings have prompted a study of leukemia incidence at the Louisiana location.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10914340     DOI: 10.1097/00043764-200007000-00006

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  2 in total

1.  Occupational cancer in Britain. Haematopoietic malignancies: leukaemia, multiple myeloma, non-Hodgkins lymphoma.

Authors:  Terry Brown; Lesley Rushton
Journal:  Br J Cancer       Date:  2012-06-19       Impact factor: 7.640

2.  Increased Standardised Incidence Ratio of Malignant Pleural Mesothelioma in Taiwanese Asbestos Workers: A 29-Year Retrospective Cohort Study.

Authors:  Cheng-Kuan Lin; Yu-Ying Chang; Jung-Der Wang; Lukas Jyuhn-Hsiarn Lee
Journal:  Biomed Res Int       Date:  2015-07-28       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.